Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma(MOLTO): a multicentre, single-arm, phase 2 trial
Tedeschi A, et al.
Lancet Oncology
September 2024
Authors and Affiliates
Alessandra Tedeschi*, Anna Maria Frustaci*, Adalgisa Condoluci, Marta Coscia, Roberto Chiarle, Pier Luigi Zinzani, Marina Motta,
Gianluca Gaidano, Giulia Quaresmini, Lydia Scarfò, Gioacchino Catania, Marina Deodato, Rebecca Jones, Valentina Tabanelli, Valentina Griggio,
Georg Stüssi, Angelica Calleri, Katia Pini, Roberto Cairoli, Thorsten Zenz, Alessio Signori, Emanuele Zucca, Davide Rossi, Marco Montillo
Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center, Milan, Italy (A Tedeschi MD, A M Frustaci MD, M Deodato MD, R Cairoli MD, M Montillo MD);
Department of Oncology, Institute of Oncology Research, Bellinzona, Switzerland (A Condoluci MD, Prof D Rossi MD, K Pini BS, Prof E Zucca MD); Clinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero
Cantonale, Bellinzona, Switzerland (A Condoluci, Prof D Rossi, Prof G Stüssi MD, Prof E Zucca MD); University Division of Hematology, AOU Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy (R Jones MD, V Griggio PhD); Department of Oncology ASST Sette Laghi,\ Ospedale di Circolo, Varese, Italy (Prof M Coscia MD);Division of Hematopathology, IEO European Institute of Oncology IRCCS, Milan, Italy (Prof R Chiarle MD, V Tabanelli MD, A Calleri PhD); Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy (Prof R Chiarle); Department of Pathology, Boston Children’s Hospital, Boston, MA, USA (Prof R Chiarle); Azienda Ospedaliero–Universitaria di Bologna, Istituto di Ematologia “L e A Seràgnoli”, Bologna, Italy